Alpine Immune Sciences has been granted a patent for immunomodulatory proteins containing variant CD112, offering therapeutic benefits for immunological and oncological conditions. The proteins, encoded by specific nucleic acids, demonstrate increased binding affinity to TIGIT, as outlined in the patent claim. GlobalData’s report on Alpine Immune Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Alpine Immune Sciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Alpine Immune Sciences, Personalized cancer vaccines was a key innovation area identified from patents. Alpine Immune Sciences's grant share as of January 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.

Variant cd112 polypeptide for immunomodulation in immunological conditions

Source: United States Patent and Trademark Office (USPTO). Credit: Alpine Immune Sciences Inc

A recently granted patent (Publication Number: US11834490B2) discloses a variant CD112 polypeptide that includes an IgV domain or both an IgV domain and an IgC domain. The variant CD112 polypeptide contains specific amino acid substitutions, such as A112V or A112I, compared to the unmodified CD112 sequence. This variant CD112 polypeptide exhibits at least 85% sequence identity to the original sequence and shows increased binding affinity to the ectodomain of TIGIT compared to the unmodified CD112.

Furthermore, the patent claims cover various modifications and compositions of the variant CD112 polypeptide, including those with up to 10 amino acid modifications, sequences with higher sequence identity percentages, and specific amino acid substitutions. The patent also extends to immunomodulatory proteins and conjugates incorporating the variant CD112 polypeptide, methods of producing these proteins, engineering cells expressing the polypeptide, pharmaceutical compositions containing the variant CD112 polypeptide, and methods of modulating immune responses in subjects using the disclosed compositions. Overall, the patent provides a comprehensive framework for utilizing the variant CD112 polypeptide and related proteins in immunomodulation and therapeutic interventions.

To know more about GlobalData’s detailed insights on Alpine Immune Sciences, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies